Omnicell, Inc. (OMCL) fair value analysis
Nasdaq · Updated 2026-10-19
OMCL price how computed
Forward Fair Value verdict
UndervaluedOMCL is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $35.39
- Sector
- Healthcare
- 12-month range
- $29.57–$51.39
- Market cap
- $1.61B
- From 52-week high
- -31.1%
- Shares outstanding
- 45.5M
- Rank in Healthcare by discount to fair value
- #36 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Omnicell, Inc. is a healthcare technology company that develops and provides automated medication and supply management solutions for healthcare facilities. The company operates globally, serving hospitals, pharmacies, and other healthcare organizations across multiple countries.
OMCL currently ranks #36 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.61B
- P/E (trailing)
- 16x
- Revenue (TTM)
- $1.25B
- Net margin
- 3.1%
- EPS (TTM)
- $2.16
- Gross margin
- 49.0%
- Debt / equity
- 0.15
- Revenue growth (3-yr avg)
- 1.5%
- Shares outstanding
- 45.5M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 60 · neutral
- 50-day average
- $34.61
- 200-day average
- $39.63
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+125.8%)
2026-03 ▲ beat (+66.7%)
2025-12 ▼ miss (-20.0%)
2025-09 ▲ beat (+41.7%)
2025-06 ▲ beat (+66.7%)
2025-03 ▲ beat (+30.0%)
2024-12 ▲ beat (+3.4%)
2024-09 ▲ beat (+33.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $57.9
- Target vs last price
- +63.6%
What our data shows for OMCL
- Our model validated 17 trailing price-to-earnings windows for OMCL, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $29.57–$51.39.
- The 14-day relative strength index sits at a neutral 60.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for OMCL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent OMCL news
TickrTrends' derived news-sentiment signal for OMCL is currently leaning positive, computed from recent coverage.
- Is Omnicell Inc (OMCL) a Bargain After 4.1% Drop? GF Value Says Undervalued (gurufocus.com, 2026-09-11)
TickrTrends take: Omnicell operates in the Healthcare sector where operational efficiency and technological adoption drive long-term value creation. TickrTrends' current assessment aligns with the market's recent pullback, maintaining an Undervalued verdict that suggests the stock may offer an attractive entry point for investors focused on valuation metrics. A valuation-focused reader should monitor whether the company's fundamentals in automation and medication management systems justify this undervalued positioning or if additional weakness may emerge. - OMCL Looks 9.4% Undervalued on GF Value™ (gurufocus.com, 2026-09-03)
TickrTrends take: TickrTrends currently rates OMCL as undervalued, which aligns with recent GF Value analysis suggesting approximately 9 percent undervaluation in the Healthcare sector. For investors focused on valuation metrics, the consistency between these independent assessments may warrant monitoring whether the market eventually reprices the stock toward its estimated fair value. The ongoing gap between current market price and calculated intrinsic value represents the key metric to track as fundamental conditions evolve. - TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations (manilatimes.net, 2026-09-03)
TickrTrends take: Omnicell's integration of a DSCSA compliance solution with TraceLink addresses a regulatory requirement that hospitals must implement, potentially creating recurring revenue opportunities in the Healthcare sector. Given TickrTrends' undervalued assessment, investors should monitor whether this partnership translates into customer adoption metrics and contract value, as successful integration into hospital pharmacy workflows could strengthen the company's competitive positioning. The expansion of compliance-focused offerings may also indicate a shift toward higher-margin software and services revenue streams that could influence future earnings quality.
What people are saying
Follow the OMCL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — OMCL has seen two notable shifts in its derived indicators this week. The 50/200-day trend state has moved from a downtrend to a mixed state, suggesting reduced directional conviction in the price momentum. Additionally, the quality grade has declined from A to B, indicating a decrease in the underlying fundamental strength metrics tracked by TickrTrends. Despite these deteriorations, the current valuation verdict remains Undervalued.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for OMCL showed a shift this week in the DCF cross-check band assessment, moving from an undervalued reading to a fairly valued reading. The current valuation verdict remains undervalued overall. This adjustment in the DCF cross-check band represents a narrowing in the gap between OMCL's market price and its intrinsic value estimate.
- 2026-09-21 — # OMCL Weekly Indicator Summary TickrTrends' derived indicators for OMCL show a shift in valuation assessment this week, with the DCF cross-check band moving from a fairly valued designation to undervalued. The current valuation verdict positions OMCL as undervalued within the healthcare sector. This change in the DCF cross-check band represents a tightening or adjustment in the fundamental value range relative to the stock's current market price.
- 2026-09-17 — TickrTrends' derived indicators for OMCL show a shift in valuation assessment this week. The DCF cross-check band has moved from an undervalued rating to a fairly valued rating, indicating that intrinsic value estimates have narrowed relative to the current market price. Despite this change in the DCF cross-check band, the current overall valuation verdict for the Healthcare sector company remains undervalued.
Frequently asked questions
Is OMCL stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), OMCL is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is OMCL's TickrTrends verdict?
OMCL's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does OMCL compare to other Healthcare stocks?
OMCL ranks #36 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is OMCL overbought or oversold?
OMCL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does OMCL report earnings next?
OMCL's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does OMCL usually beat earnings estimates?
Over its last 8 reported quarters OMCL beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about OMCL?
Of 8 analysts covering OMCL, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $57.9 (+63.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
OMCL vs BAX · OMCL vs BDX · OMCL vs BTSG · OMCL vs EW · OMCL vs HALO